Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Read post on prnewswire.com

- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - TOKYO, Sept. 23, 2026 /PRNewswire/ --...